Amolyt Pharma’s Eneboparatide Receives the US FDA’s Fast Track Designation for Hypoparathyroidism
Shots:
- The US FDA has granted fast track designation to the company’s eneboparatide for treating hypoparathyroidism
- Eneboparatide is being developed under the P-III (Calypso) trial to investigate its safety & efficacy for treating chronic hypoparathyroidism patients (n=165). The topline results are anticipated in 2025
- Eneboparatide works by binding with the PTH receptor to stabilize blood calcium levels and reduce urine calcium excretion thus managing the hypoparathyroidism symptoms. It aims at preventing kidney function decline and chronic kidney disease development
Ref: Amolyt Pharma | Image: Amolyt Pharma
Related News:- Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
